Read by QxMD icon Read

rituximab hepatitis b reactivation

Maria R Ciardi, Marco Iannetta, Maria A Zingaropoli, Romina Salpini, Marianna Aragri, Rosanna Annecca, Simona Pontecorvo, Marta Altieri, Gianluca Russo, Valentina Svicher, Claudio M Mastroianni, Vincenzo Vullo
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients...
January 2019: Open Forum Infectious Diseases
Linda Drößler, Clara Lehmann, Karin Töpelt, Dirk Nierhoff, Jörg J Vehreschild, Jan Rybniker, Michael Hallek, Julia Fischer, Verena Stormberg, Gerd Fätkenheuer, Ulrike Wieland, Norma Jung
Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations...
January 28, 2019: Infection
Mustafa Karaca, Deniz Tural, Emre Akar, İbrahim Çil, Savaş Bayrak, Gulsum Ozet, Orhan Kemal Yucel, Erhan Hocaoglu, Ahmet Ozet
OBJECTIVE: The reactivation rate of chronic hepatitis B virus infection in cancer patients and chemotherapy regimens thought to be associated with hepatitis reactivation were investigated. PATIENTS AND METHODS: In all, 3,890 cancer patients were included in this study. Mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were obtained. RESULTS: Only 354 patients had positive hepatitis serology results (HBsAg+)...
November 8, 2018: Chemotherapy
Arturo Ciccullo, F R Ponziani, E Maiolo, F Pallavicini, M Pompili
BACKGROUND: Hepatitis B virus (HBV) reactivation is commonly observed in HBsAg-positive hematologic patients undergoing immunosuppressive chemotherapy. Recent guidelines recommend antiviral prophylaxis to be continued for up to 12 months after the discontinuation of the anticancer regimen. CASE PRESENTATION: We report a case of a patient who underwent antiviral prophylaxis for 26 months after the discontinuation of a rituximab-containing chemotherapy regimen for a lymphoma and was admitted in the infectious diseases department with a 3-day history of jaundice, itching, and dark urine...
October 27, 2018: Infection
Juhan Lee, Jun Yong Park, Deok Gie Kim, Jee Youn Lee, Beom Seok Kim, Myoung Soo Kim, Soon Il Kim, Yu Seun Kim, Kyu Ha Huh
Sensitized patients received desensitization therapy with rituximab for kidney transplantation. However, the impact of rituximab dose on hepatitis B virus (HBV) reactivation is unknown. Patients who underwent living donor kidney transplantation between 2008 and 2016 were grouped according to rituximab dose (control vs. standard-dose rituximab [375 mg/m2 ] vs. reduced-dose rituximab [200 mg/body]) for comparison of HBV reactivation. A total of 336 hepatitis B surface antigen (HBsAg)-negative/antibody to hepatitis B core antigen (anti-HBc)-positive patients underwent kidney transplantation, of whom 91 (27...
October 23, 2018: Scientific Reports
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G Peters, Yasuhito Tanaka, Andrew D Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai
Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-containing immunochemotherapy in the phase 3 GOYA and GALLIUM studies. HBV DNA monitoring was undertaken monthly to 1 year after the last dose of study drug. In case of HBV reactivation (confirmed, HBV DNA ≥29 IU/mL), immunochemotherapy was withheld and nucleos(t)ide analog treatment (preemptive NAT) started...
January 10, 2019: Blood
Alessandro Loglio, Mauro Viganò, Glenda Grossi, Sara Labanca, Maria Goldaniga, Alessandra Pompa, Lucia Farina, Mariagrazia Rumi, Paolo Corradini, Floriana Facchetti, Giovanna Lunghi, Luca Baldini, Pietro Lampertico
BACKGOUND: A significant proportion of hepatitis B surface antigen (HBsAg) negative/anti-hepatitis B core antigen (anti-HBc) positive patients with non-Hodgkin lymphoma (NHL) undergoing rituximab-based chemotherapy (R-CT) may suffer hepatitis B virus (HBV) reactivation. AIMS: We wanted to assess efficacy and safety of lamivudine (LMV) prophylaxis to prevent this complication. METHODS: Eighty-five consecutive HBsAg negative/anti-HBc positive NHL patients (71 years, 100% serum HBV DNA undetectable, 74% anti-HBs positive) received LMV coadministered with R-CT and for 18 months after the end of R-CT...
September 7, 2018: Digestive and Liver Disease
Sara Querido, André Weigert, Teresa Adragão, Luís Rodrigues, Cristina Jorge, Margarida Bruges, Domingos Machado
BACKGROUND: Previous contact with Hepatitis B virus (HBV) is common in patients undergoing hemodialysis. Literature has shown conflicting results on the risk of HBV reactivation in kidney transplant (KT) recipients with serologic evidence of past HBV infection. METHODS: We reviewed 631 consecutive KT recipients and selected 70 patients simultaneously HBsAg negative and anti-HBc positive before KT, regardless of hepatitis B surface antibody (anti-HBs) status. Demographic characteristics, coinfection with other viruses, the presence of a previous KT, induction and maintenance immunosuppression, length of follow up, biopsy-proven acute rejection episodes, incidence of impaired liver function, and causes of graft loss and mortality were collected...
October 8, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
Emanuela Zappulo, Laura Ambra Nicolini, Carmen Di Grazia, Alida Dominietto, Teresa Lamparelli, Francesca Gualandi, Patrizia Caligiuri, Bianca Bruzzone, Emanuele Angelucci, Claudio Viscoli, Malgorzata Mikulska
PURPOSE: Hepatitis B virus (HBV) reactivation during immunosuppressive therapy is common in patients with hematological malignancies, even in case of resolved infection. Prophylaxis of HBV reactivation is universally recommended in stem cell transplant (SCT) recipients and patients treated with anti-CD20 agents (i.e., rituximab). Despite its well-established favorable safety profile, lamivudine (LAM) use in prophylaxis has been debated because of the possible emergence of resistant viral strains...
September 19, 2018: Infection
Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Ken Okai, Atsushi Takahashi, Hiromasa Ohira
Hepatitis B virus (HBV) reactivation occasionally occurs long after immunosuppressive therapy. The characteristics of late HBV reactivation remain unclear. We herein present a case of HBV reactivation in a patient with nonalcoholic steatohepatitis (NASH) more than 3 years after rituximab-containing chemotherapy for diffuse large B-cell lymphoma. Increased transaminase levels, which were induced by NASH, were observed after chemotherapy and were alleviated with statin treatment. HBV reactivation was identified incidentally...
September 12, 2018: Internal Medicine
Kashif Ali, Ali Akbar Sial, Mirza Tasawer Baig, Nida Baig, Saqib Hussain Ansari, Tahir Sultan Shamsi
Background: Reactivation of hepatitis B virus (HBV) and hepatitis C virus (HCV) and febrile neutropenia (FN) are common in diffuse large B-cell lymphoma (DLBCL) patients undergoing cyclophosphamide, hydroxyrubicin, Oncovin, and prednisolone (CHOP) or cyclophosphamide, hydroxyrubicin, Oncovin, prednisolone - rituximab containing (R-CHOP) chemotherapy. This ultimately leads to delaying the therapy, increasing hospital stay, and raising the pharmacoeconomic burden on patients. Aim and Objective: The aim of this study was to determine the incidence of HBV and HCV infection and febrile neutropenia in DLBCL patients treated with R-CHOP and CHOP...
June 2018: Hospital Pharmacy
Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, Ming-Zhi Zhang, Wei Li, Yu Hu, Xiao-Hong Zhang, Yu-Huan Gao, Zuo-Xing Niu, Ru Feng, Wei Wang, Jie-Wen Peng, Xiao-Lin Li, Xue-Nong Ouyang, Chang-Ping Wu, Wei-Jing Zhang, Yun Zeng, Zhen Xiao, Ying-Min Liang, Yong-Zhi Zhuang, Ji-Shi Wang, Zi-Min Sun, Hai Bai, Tong-Jian Cui, Ji-Feng Feng
Background: Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes of rituximab plus chemotherapy (R-chemo) as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus (HBV) reactivation management was also investigated. Methods: A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in China was conducted between January 17, 2011 and October 31, 2016...
August 5, 2018: Chinese Medical Journal
Evangelos Cholongitas, Anna-Bettina Haidich, Fani Apostolidou-Kiouti, Parthenis Chalevas, George V Papatheodoridis
Background: The optimal management of HBsAg-negative, anti-HBc-positive patients who receive immunosuppression remains unclarified. We systematically reviewed the available data on potential predictors of the risk of hepatitis B virus (HBV) reactivation in such patients. Methods: A literature search identified 55 studies with 3640 HBsAg-negative, anti-HBc-positive patients who received immunosuppressive regimens. Results: HBV reactivation was reported in 236 (6...
July 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
Mubarak M Al-Mansour, Saif A Alghamdi, Musab A Alsubaie, Abdullah A Alesa, Muhammad A Khan
Background: Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy...
2018: Infectious Agents and Cancer
María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban
[This corrects the article DOI: 10.1371/journal.pone.0184550.].
2018: PloS One
Denise Yeo, Ihtimam Hossain, Soon Thye Lim, Mohamad Farid, Miriam Tao, Richard Quek, Tiffany Tang, Alexandre Chan
No abstract text is available yet for this article.
September 2018: Journal of Oncology Pharmacy Practice
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu
BACKGROUND: Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. METHODS: PubMed, the Cochrane library, and the ClinicalTrials...
September 2018: European Journal of Clinical Pharmacology
Zarak H Khan, Kamran Ilyas, Haider Ghazanfar, Hamza H Khan, Qulsoom Hussain, Sahla Hammad, Ahmed Munir, Rizwan Asim
The objective of our study was to recognize hepatitis B reactivation as a complication of rituximab chemotherapy and to realize the importance of screening for prior Hepatitis B virus (HBV) exposure in all patients with hematologic malignancies who will receive rituximab as part of their therapy. Rituximab is a monoclonal antibody targeting CD 20 receptors on the membrane of B cells. In this case report, we described a 79-year-old man who presented to our department with nausea, fatigue, and jaundice. Two months ago, he had received the last dose of the chemotherapy regimen containing rituximab for follicular B cell lymphoma...
March 2, 2018: Curēus
Michele Spinicci, Giacomo Emmi, Laura Dies, Alessandro Barilaro, Gianfranco Vitiello, Jessica Mencarini, Annalisa Cavallo, Alessandro Bartoloni, Filippo Bartalesi
OBJECTIVES: Rituximab (RTX) is a monoclonal antibody that is widely used in hematologic malignancies and immune-mediated diseases (IMID) and has been associated with the risk of hepatitis B virus reactivation (HBVr). Thus, antiviral prophylaxis is recommended before RTX treatment in all patients with chronic hepatitis B virus (HBV) infection and those with resolved infection affected by onco-hematological conditions. By contrast, the correct management of HBsAg-negative/HbcAb-positive patients candidates for RTX-containing regimens for IMID is still debated, owing to few data currently available in this setting...
July 2018: European Journal of Gastroenterology & Hepatology
Yi-Chia Su, Pei-Chin Lin, Hsien-Chung Yu, Chih-Chien Wu
BACKGROUND: The role of antiviral prophylaxis before chemotherapy or immunosuppressive therapy to prevent hepatitis B virus (HBV) reactivation in patients with resolved HBV infection [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc) positive] is unclear. This study aimed to evaluate the efficacy of prophylactic antiviral therapy and outcomes of HBsAg-negative, anti-HBc-positive patients who received chemotherapy or immunosuppressive therapy. PATIENTS AND METHODS: We retrospectively evaluated the medical records of HBsAg-negative, anti-HBc-positive patients who underwent chemotherapy or immunosuppressive therapy from January 2013 through November 2016 at a single institute in southern Taiwan...
August 2018: European Journal of Gastroenterology & Hepatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"